Inclusion Criteria:

          -  Patients with a metastatic breast adenocarcinoma HER2+, a metastatic squamous
             carcinoma of VADS, or a colorectal adenocarcinoma with a wild status for RAS (NRAS and
             KRAS)

          -  Patient presenting at least two measurable metastases (according to the RECIST v1.1
             criteria):

          -  At least one eligible to SBRT (hepatic, pulmonary, bone or intra-cranial metastasis,
             with a diameter between 1 and 4cm)

          -  At least one non irradiated measurable metastasis

          -  Performance Status corresponding to 0, 1, or 2

          -  Realisation of a PET (Positron Emission Tomography)-Scanner and a TAP
             (Thoraco-AbdominoPelvic)-Scanner 30 days maximum before inclusion

          -  Informed consent patient

          -  Patients affiliated to a social security scheme.

        Exclusion Criteria:

          -  Patient presenting a known non-indication or contraindication to the first line
             treatment administered

          -  Pregnant or nursing women

          -  Patient with an another cancer during the 5 last years, excepting basocellular
             carcinoma, and skin epidermoid carcinoma

          -  Patient presenting a non-controlled pain linked to the cancer

          -  Patient presenting a non-controlled hypercalcemia or symptomatic hypercalcemia needing
             an ongoing use of bisphosphonates or denosumab.

          -  Patient presenting an inflammatory pathology or active autoimmune pathology or history
             of.

          -  Patient having received one or more vaccines during the 4 weeks preceding the
             beginning of the systemic treatment.

          -  Patient currently using corticosteroids or other immune-suppressors during the two
             weeks before inclusion, and any other situation where this kind of treatments could be
             necessary during the study.

          -  Patient deprive of liberty or under administrative supervision, patients with an
             impossible take care supervision for psychological or geographical reasons.

          -  Stereotactic Body Radio-Therapy (SBRT) must not include metastases localized in the 3
             centimeters of the structure previously irradiated.

          -  Patient presenting serious active comorbidities defined by the protocol.

          -  Known seropositivity to the HIV